105 related articles for article (PubMed ID: 17196996)
21. Enhanced behavioral sensitivity to the competitive GABA agonist, gaboxadol, in transgenic mice over-expressing hippocampal extrasynaptic alpha6beta GABA(A) receptors.
Saarelainen KS; Ranna M; Rabe H; Sinkkonen ST; Möykkynen T; Uusi-Oukari M; Linden AM; Lüddens H; Korpi ER
J Neurochem; 2008 Apr; 105(2):338-50. PubMed ID: 18021290
[TBL] [Abstract][Full Text] [Related]
22. EEG spectral power density profiles during NREM sleep for gaboxadol and zolpidem in patients with primary insomnia.
Lundahl J; Deacon S; Maurice D; Staner L
J Psychopharmacol; 2012 Aug; 26(8):1081-7. PubMed ID: 22057018
[TBL] [Abstract][Full Text] [Related]
23. Extrasynaptic GABAA receptors are critical targets for sedative-hypnotic drugs.
Orser BA
J Clin Sleep Med; 2006 Apr; 2(2):S12-8. PubMed ID: 17557502
[TBL] [Abstract][Full Text] [Related]
24. Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance.
Voss J; Sanchez C; Michelsen S; Ebert B
Eur J Pharmacol; 2003 Dec; 482(1-3):215-22. PubMed ID: 14660025
[TBL] [Abstract][Full Text] [Related]
25. Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia.
Lundahl J; Staner L; Staner C; Loft H; Deacon S
Psychopharmacology (Berl); 2007 Nov; 195(1):139-46. PubMed ID: 17653697
[TBL] [Abstract][Full Text] [Related]
26. Alterations in cyclic alternating pattern associated with phase advanced sleep are differentially modulated by gaboxadol and zolpidem.
Svetnik V; Ferri R; Ray S; Ma J; Walsh JK; Snyder E; Ebert B; Deacon S
Sleep; 2010 Nov; 33(11):1562-70. PubMed ID: 21102998
[TBL] [Abstract][Full Text] [Related]
27. Effect of microdialysis perfusion of 4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridine-3-ol in the perifornical hypothalamus on sleep-wakefulness: role of delta-subunit containing extrasynaptic GABAA receptors.
Thakkar MM; Winston S; McCarley RW
Neuroscience; 2008 May; 153(3):551-5. PubMed ID: 18406065
[TBL] [Abstract][Full Text] [Related]
28. Postnatal development and kinetics of [3H]gaboxadol binding in rat brain: in vitro homogenate binding and quantitative autoradiography.
Friemel A; Ebert B; Hutson PH; Brust P; Nieber K; Deuther-Conrad W
Brain Res; 2007 Sep; 1170():39-47. PubMed ID: 17692833
[TBL] [Abstract][Full Text] [Related]
29. Plasma and CNS concentrations of Gaboxadol in rats following subcutaneous administration.
Cremers T; Ebert B
Eur J Pharmacol; 2007 May; 562(1-2):47-52. PubMed ID: 17362924
[TBL] [Abstract][Full Text] [Related]
30. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia.
Walsh JK; Perlis M; Rosenthal M; Krystal A; Jiang J; Roth T
J Clin Sleep Med; 2006 Jan; 2(1):35-41. PubMed ID: 17557435
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain.
Munro G; Lopez-Garcia JA; Rivera-Arconada I; Erichsen HK; Nielsen EØ; Larsen JS; Ahring PK; Mirza NR
J Pharmacol Exp Ther; 2008 Dec; 327(3):969-81. PubMed ID: 18791060
[TBL] [Abstract][Full Text] [Related]
32. Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity.
Stórustovu Sí; Ebert B
Eur J Pharmacol; 2003 Apr; 467(1-3):49-56. PubMed ID: 12706454
[TBL] [Abstract][Full Text] [Related]
33. Post-bedtime dosing with indiplon in adults and the elderly: results from two placebo-controlled, active comparator crossover studies in healthy volunteers.
Farber RH; Burke PJ
Curr Med Res Opin; 2008 Mar; 24(3):837-46. PubMed ID: 18257978
[TBL] [Abstract][Full Text] [Related]
34. Status epilepticus alters zolpidem sensitivity of [3H]flunitrazepam binding in the developing rat brain.
Laurén HB; Lopez-Picon FR; Kukko-Lukjanov TK; Uusi-Oukari M; Holopainen IE
Neuroscience; 2007 May; 146(2):802-11. PubMed ID: 17360122
[TBL] [Abstract][Full Text] [Related]
35. Selectivity in generalization to GABAergic drugs in midazolam-trained baboons.
Ator NA
Pharmacol Biochem Behav; 2003 May; 75(2):435-45. PubMed ID: 12873636
[TBL] [Abstract][Full Text] [Related]
36. WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation.
Marona-Lewicka D; Nichols DE
Behav Pharmacol; 2009 Feb; 20(1):114-8. PubMed ID: 19179855
[TBL] [Abstract][Full Text] [Related]
37. In vivo saturation binding of GABA-A receptor ligands to estimate receptor occupancy using liquid chromatography/tandem mass spectrometry.
Hopkins SC; Brian Nofsinger J; Allen MS; Koch P; Varney MA
Biopharm Drug Dispos; 2009 Jan; 30(1):9-20. PubMed ID: 19152227
[TBL] [Abstract][Full Text] [Related]
38. The monoamine oxidase inhibitor phenelzine enhances the discriminative stimulus effect of nicotine in rats.
Wooters TE; Bardo MT
Behav Pharmacol; 2007 Nov; 18(7):601-8. PubMed ID: 17912044
[TBL] [Abstract][Full Text] [Related]
39. Effect of the GABAA agonist gaboxadol on nocturnal sleep and hormone secretion in healthy elderly subjects.
Lancel M; Wetter TC; Steiger A; Mathias S
Am J Physiol Endocrinol Metab; 2001 Jul; 281(1):E130-7. PubMed ID: 11404230
[TBL] [Abstract][Full Text] [Related]
40. Potential roles of GABA receptors in morphine self-administration in rats.
Yoon SS; Lee BH; Kim HS; Choi KH; Yun J; Jang EY; Shim I; Kim JA; Kim MR; Yang CH
Neurosci Lett; 2007 Nov; 428(1):33-7. PubMed ID: 17945420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
